Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04933630 · ClinicalTrials.gov registry record
Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study
A clinical trial, sponsored by Adams Clinical.
- Completed
- Registry status
- 27
- Enrollment target
NCT04933630: Completed study, sponsored by Adams Clinical.
NCT04933630 is a clinical trial that has completed, run by Adams Clinical. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04933630 has completed, sponsored by Adams Clinical.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
TRAIT-RS is an observational study to evaluate ongoing treatment response stability to standard of care antidepressant treatments (ADTs) among individuals who met criteria for Major Depressive Disorder (MDD) and completed the Tracking Response to Antidepressants in Advance of Investigational Trials (TRAIT) study (NCT04748276).
Interventions
- DRUG FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2022-10-05 |
What the finished NCT04933630 record still lists
NCT04933630 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) is the first listed.
NCT04933630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04933630 about?
NCT04933630 is a clinical study titled "Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study". TRAIT-RS is an observational study to evaluate ongoing treatment response stability to standard of care antidepressant treatments (ADTs) among individuals who met criteria for Major Depressive Disorder (MDD) and completed the Tracking Response to Antidepressants in Advance of Investigational Trials ...
What is the current status of trial NCT04933630?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2021-06-01. Estimated completion is 2022-10-05.
What interventions are being tested in trial NCT04933630?
The interventions under investigation include: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) (DRUG).
Who is sponsoring clinical trial NCT04933630?
This trial is sponsored by Adams Clinical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI